Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1114

1.

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.

Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.

Int J Chron Obstruct Pulmon Dis. 2012;7:201-9. doi: 10.2147/COPD.S25805. Epub 2012 Mar 15.

2.
3.

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K.

Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:889-904. doi: 10.2147/COPD.S62750. eCollection 2014.

4.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.

Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19.

5.

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study.

Kozma CM, Paris AL, Plauschinat CA, Slaton T, Mackowiak JI.

BMC Pulm Med. 2011 Dec 22;11:61. doi: 10.1186/1471-2466-11-61.

6.

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).

Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T.

Cochrane Database Syst Rev. 2017 Feb 10;2:CD012066. doi: 10.1002/14651858.CD012066.pub2. Review.

PMID:
28185242
7.

Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort.

Jochmann A, Scherr A, Jochmann DC, Miedinger D, Török SS, Chhajed PN, Tamm M, Leuppi JD.

Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567.

8.

Predictors of ICS/LABA prescribing in COPD patients: a study from general practice.

Drivenes E, Ostrem A, Melbye H.

BMC Fam Pract. 2014 Mar 5;15:42. doi: 10.1186/1471-2296-15-42.

9.

Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.

Wurst KE, Shukla A, Muellerova H, Davis KJ.

COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19.

PMID:
24945236
10.

Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study.

Wurst KE, St Laurent S, Mullerova H, Davis KJ.

Int J Chron Obstruct Pulmon Dis. 2014 Sep 25;9:1021-31. doi: 10.2147/COPD.S58258. eCollection 2014.

11.

Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study.

Manoharan A, Short PM, Anderson WJ, Lipworth BJ.

Lung. 2014 Oct;192(5):649-52. doi: 10.1007/s00408-014-9611-8. Epub 2014 Jun 22.

PMID:
24952426
12.

Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.

Cyr MC, Beauchesne MF, Lemière C, Aaron SD, Blais L.

Ann Pharmacother. 2010 Apr;44(4):613-22. doi: 10.1345/aph.1M243. Epub 2010 Mar 16.

PMID:
20233915
13.

Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.

Kew KM, Dias S, Cates CJ.

Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.

PMID:
24671923
14.

Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.

Kew KM, Dahri K.

Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011721. doi: 10.1002/14651858.CD011721.pub2. Review.

PMID:
26798035
15.
16.

Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).

Cecere LM, Slatore CG, Uman JE, Evans LE, Udris EM, Bryson CL, Au DH.

COPD. 2012 Jun;9(3):251-8. doi: 10.3109/15412555.2011.650241. Epub 2012 Apr 12.

PMID:
22497533
17.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M.

Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30.

18.

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.

Singh MP.

Int J Chron Obstruct Pulmon Dis. 2013;8:613-9. doi: 10.2147/COPD.S53707. Epub 2013 Dec 9.

19.

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.

Hizawa N.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 10;10:1093-102. doi: 10.2147/COPD.S72858. eCollection 2015. Review.

20.

Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.

Ohar JA, Donohue JF.

Semin Respir Crit Care Med. 2010 Jun;31(3):321-33. doi: 10.1055/s-0030-1254072. Epub 2010 May 21. Review.

PMID:
20496301

Supplemental Content

Support Center